About
Protein Degradation Cancer Treatments
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
3
As Collaborator
2
Total Enrollment
89
By Phase
PHASE1: 2PHASE2: 1PHASE1/PHASE2: 2
By Status
COMPLETED: 2UNKNOWN: 2RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06964009Collaborator
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
PHASE1Recruiting
30 participants
Started: Sep 22, 2025 · Completed: Dec 30, 2027
NCT04886622Lead Sponsor
A Study of DT2216 in Relapsed/Refractory Malignancies
PHASE1Completed
20 participants
Started: Aug 25, 2021 · Completed: Jun 30, 2024
NCT00006656Lead Sponsor
Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
PHASE2Unknown
Started: Jun 30, 2000
NCT00009854Lead Sponsor
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
PHASE1/PHASE2Unknown
Started: Jun 30, 2000
NCT00038441Collaborator
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
PHASE1/PHASE2Completed
39 participants
Started: Sep 30, 1995 · Completed: Aug 31, 2005
Locations (1)
Headquarters
Dallas, TX, United States
Map
Loading map...